DFT383 in partecipanti pediatrici con cistinosi nefropatica (CYStem)
Uno studio di etichetta aperta, multicentrica, fase I/II per valutare la sicurezza, la tollerabilità e l'efficacia di DFT383 nei partecipanti pediatrici con cistinosi nefropatica
An open-label, multi-center, phase I/II study to assess the safety, tolerability and efficacy of DFT383 in pediatric participants with nephropathic cystinosis, followed by a long-term extension phase.
The purpose of this clinical study is to assess safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis. The study consists of a Core Phase and a long-term Extension Phase. DFT383 is a cellular gene therapy.
This study includes an active arm (Cohort 1) of participants treated with study treatment DFT383 and a concurrent reference arm (Cohort 0). Participants in Cohort 0 will not receive study treatment and will only participate in the Core Phase of the study. The study is not randomized and Cohort 0 aims to collect prospective and concurrent data in this rare disease.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This study is an open-label, multi-center, phase I/II study to assess the safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis, followed by a long-term extension phase.
The study includes two Treatment Groups (Cohort 1 and Cohort 0) and consists of a Core Phase and a long-term Extension Phase.
Participants in Cohort 1 will receive DFT383 and participate in both the Core and Extension Phase. Participants in Cohort 0 will not receive study treatment and will participate in the Core Phase only.
The two cohorts will be run in parallel. Investigational sites may participate in one or both cohorts.
Cohort 1 Approximately 15 participants will receive treatment with DFT383 in 3 (sub) cohorts (1A, 1B and 1C) dosed in a staggered approach. The total study duration for a participant in Cohort 1 will be up to 32 months in the core phase and up to 13 years for the long-term extension phase.
Cohort 0 Approximately 15 participants meeting similar inclusion/exclusion criteria and receiving SoC will be enrolled. The Schedule of Activities will be reduced for this Cohort. This cohort 0 is not a direct control but will provide essential context for interpreting the results observed in the participants receiving DFT383. The total study duration for a participant in Cohort 0 will be up to 24 months.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Novartis Pharmaceuticals
- Numero di telefono: 1-888-669-6682
- Email: novartis.email@novartis.com
Backup dei contatti dello studio
- Nome: Novartis Pharmaceuticals
Luoghi di studio
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85016
- Reclutamento
- Phoenix Children's Hospital (Recruiting Cohort 0 and 1)
-
Contatto:
- Erica Sieber
- Numero di telefono: 602-933-0171
- Email: esieber@phoenixchildrens.com
-
Investigatore principale:
- Shanna White
-
-
California
-
San Diego, California, Stati Uniti, 92123
- Reclutamento
- University of California at San Diego - Rady Children's Hospital (Recruiting Cohort 0 and 1)
-
Contatto:
- Mieko Pretlow
- Numero di telefono: Ext 226010 858-966-1700
- Email: mpretlow@rchsd.org
-
Investigatore principale:
- Nadine Benador nbenador@health.ucsd.edu
-
Stanford, California, Stati Uniti, 94305
- Reclutamento
- Stanford University - Stanford Children's Health (Recruiting Cohort 0 and 1)
-
Investigatore principale:
- Alice Bertaina
-
Contatto:
- Research Nurse
- Numero di telefono: (650) 725-9032
- Email: scgt_clinical_trials_office@lists.stanford.edu
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Emory University School of Medicine - Children's Healthcare of Atlanta (recuiting Cohort 0)
-
Investigatore principale:
- Laurence (Larry) Greenbaum
-
Contatto:
- Laurence (Larry) Greenbaum
- Numero di telefono: 404-712-6374
- Email: lgreen6@emory.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- Children's Hospital of Philadelphia (Recruiting Cohort 0)
-
Contatto:
- Melissa Cadnapaphornchai
- Numero di telefono: 215-590-2449
-
Investigatore principale:
- Melissa Cadnapaphornchai
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Baylor College of Medicine - Texas Children's Hospital (recuiting Cohort 0)
-
Contatto:
- Ewa Elenberg
- Numero di telefono: 832-824-3800
- Email: Email_elenberg@bcm.edu
-
Investigatore principale:
- Ewa Elenberg
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
Participants eligible for inclusion in this study must meet all the following criteria:
- Informed consent in writing from parent(s) or legal guardian(s) must be provided
- 2 to 5 years of age (including 5 years and 364 days old) at Screening
- Weight-for-stature is ≥ the third percentile, and is ≥ 10 kg
- Oral cysteamine therapy for at least 6 months
- Historic clinical diagnosis of nephropathic cystinosis
- Laboratory evidence of of renal fanconi syndrome (RFS)
- Relatively preserved kidney function (eGFR ≥ 60mL/min/1.73m2)
- Received all age-appropriate vaccinations
Key exclusion Criteria for Cohort 1 and 0
- A history of kidney transplantation
- A prior or planned bone marrow or stem cell transplantation or prior treatment with gene therapy
- History of malignancy
- A severe or uncontrolled medical disorder
- Major surgery within 90 days
Additional Key exclusion criteria for Cohort 1 - The following exclusion criterion applies to Cohort 1 only as it is related to DFT383 treatment:
1. Indomethacin within 2 weeks prior to Screening
Other protocol-defined inclusion/exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Cohort 1 (DFT383)
Treatment with DFT383 |
DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy. |
|
Nessun intervento: Cohort 0 (SoC)
No study treatment, will continue with standard of care (cysteamine). |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Core Phase - Incidence of adverse events (Cohort 1)
Lasso di tempo: Up to 32 months
|
Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs) |
Up to 32 months
|
|
Core Phase - Number of participants with hematological reconstitution (Cohort 1)
Lasso di tempo: 42 days post DFT infusion
|
Hematological reconstitution by Day 42 post-DFT383 infusion |
42 days post DFT infusion
|
|
Core Phase - Proportion of participants with reversal of renal Fanconi syndrome (RFS)
Lasso di tempo: Up to 32 months
|
Proportion of participants with reversal of renal Fanconi syndrome (RFS) |
Up to 32 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Core Phase - Number of participants independent from cysteamine
Lasso di tempo: up to 24 months
|
Independence from oral and ophthalmic cysteamine |
up to 24 months
|
|
Core Phase - Health-related quality of life (HRQOL)
Lasso di tempo: Up to 32 months
|
Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development |
Up to 32 months
|
|
Core Phase - Time from infusion to reversal of RFS (Cohort 1)
Lasso di tempo: Up to 24 months
|
Time from infusion to reversal of renal Fanconi syndrome (RFS) |
Up to 24 months
|
|
Core Phase - Time from screening to reversal of RFS (Cohort 0)
Lasso di tempo: Up to 24 months
|
Time from screening to reversal of renal Fanconi syndrome (RFS) |
Up to 24 months
|
|
Core Phase - Duration of reversal of RFS
Lasso di tempo: Up to 24 months
|
Duration of reversal of renal Fanconi syndrome (RFS) |
Up to 24 months
|
|
Core Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR)
Lasso di tempo: Up to 27 months
|
Change from baseline on urine protein to creatinine ratio (UPr/CR) |
Up to 27 months
|
|
Core Phase - Change from baseline on urine amino acids
Lasso di tempo: Up to 27 months
|
Change from baseline on urine amino acids |
Up to 27 months
|
|
Core Phase - Change from baseline on urinary glucose to creatinine ratio
Lasso di tempo: Up to 27 months
|
Change from baseline on urinary glucose to creatinine ratio |
Up to 27 months
|
|
Core Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR)
Lasso di tempo: Up to 27 months
|
Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio |
Up to 27 months
|
|
Core Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr)
Lasso di tempo: Up to 27 months
|
Change from baseline on urine retinol-binding protein/creatinine ratio |
Up to 27 months
|
|
Core Phase - Number of participants with improvement of proximal tubular function
Lasso di tempo: Up to 27 months
|
Improvement of proximal tubular function as defined by 2-fold change from Baseline of at least 4 out of 5 RFS parameters (urine protein to creatinine ratio, urine amino acids, urinary glucose to creatinine ratio, tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate, urine retinol-binding protein/creatinine ratio). Improvement will also be considered if the change from Baseline is less than 2-fold but the value falls within the definition for normalization. |
Up to 27 months
|
|
Core Phase - Corneal cystine crystal content
Lasso di tempo: Up to 27 months
|
Corneal crystal content by anterior segment optical coherence tomography (AS-OCT) |
Up to 27 months
|
|
Core Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Lasso di tempo: Up to 27 months
|
Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG |
Up to 27 months
|
|
Core Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Lasso di tempo: Up to 27 months
|
Number of participants with presence/emergence of replication-competent lentivirus |
Up to 27 months
|
|
Core Phase - Number of participants with malignancy (Cohort 1)
Lasso di tempo: Up to 27 months
|
Number of participants with malignancy |
Up to 27 months
|
|
Core Phase - Time to hematological reconstitution (Cohort 1)
Lasso di tempo: Up to 24 months
|
Time to hematological reconstitution |
Up to 24 months
|
|
Core Phase - Time to platelet engraftment (Cohort 1)
Lasso di tempo: Up to 24 months
|
Time to platelet engraftment |
Up to 24 months
|
|
Core Phase - Incidence of Adverse Events (Cohort 0)
Lasso di tempo: up to 24 months
|
Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs) |
up to 24 months
|
|
Extension Phase Primary Objective - Incidence of Adverse events (Cohort 1)
Lasso di tempo: Up to 15 years and 8 months
|
Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs) |
Up to 15 years and 8 months
|
|
Extension Phase - Number of participants with malignancy (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months
|
Number of participants with malignancy |
Up to 15 years and 3 months
|
|
Extension Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months
|
Number of participants with presence/emergence of replication-competent lentivirus |
Up to 15 years and 3 months
|
|
Extension Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months
|
Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR) (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months
|
Change from baseline on urine protein to creatinine ratio (UPr/CR) |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urine amino acids (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months
|
Change from baseline on urine amino acids |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urinary glucose to creatinine ratio (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months
|
Change from baseline on urinary glucose to creatinine ratio |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR) (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months
|
Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr) (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months
|
Change from baseline on urine retinol-binding protein/creatinine ratio |
Up to 15 years and 3 months
|
|
Extension Phase - Duration of reversal of RFS (Cohort 1)
Lasso di tempo: Up to 15 years
|
Duration of reversal of renal Fanconi syndrome (RFS) |
Up to 15 years
|
|
Extension Phase - Number of participants with kidney failure (Cohort 1)
Lasso di tempo: Up to 15 years
|
Number of participants with kidney failure |
Up to 15 years
|
|
Extension Phase - Number of participants independent from cysteamine (Cohort 1)
Lasso di tempo: Up to 15 years
|
Independence from oral and ophthalmic cysteamine |
Up to 15 years
|
|
Extension Phase - Corneal cystine crystal content (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months
|
Corneal crystal content by anterior segment optical coherence tomography (AS-OCT) |
Up to 15 years and 3 months
|
|
Extension Phase - Health-related quality of life (HRQOL) (Cohort 1)
Lasso di tempo: Up to 15 years and 8 months
|
Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development |
Up to 15 years and 8 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Metabolismo, errori congeniti
- Malattie genetiche, congenite
- Malattie metaboliche
- Trasporto tubolare renale, errori congeniti
- Malattie e anomalie congenite, ereditarie e neonatali
- Malattie nutrizionali e metaboliche
- Cistinosi
- Sindrome di Fanconi
- Malattie da accumulo lisosomiale
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CDFT383A12101
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .